Article Details

AstraZeneca gets CDSCO panel nod to study anticancer drug Durvalumab

Retrieved on: 2022-06-03 14:38:06

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca gets CDSCO panel nod to study anticancer drug Durvalumab. View article details on hiswai:

Excerpt

New Delhi: Pharmaceutical major, AstraZeneca has got the go-ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control ...

Article found on: medicaldialogues.in

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up